

Anti-PD-1 Antibody (Gresonitamab)

Introduction

Gresonitamab is a monoclonal antibody derived from humanized antibody technology. Its composition mainly includes heavy and light chains of the IgG1 subtype. Gresonitamab specifically binds to the target molecule PD-1, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby restoring the anti-tumor activity of T cells. The drug is mainly used to treat certain types of cancer, such as non-small cell lung cancer and melanoma.

Product parameters

Alternative Names	AMG 910, Anti-Human CD3xClaudin18.2
Target Accession	-
Target	PD-1
CAS number	2413817-97-5
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

